Last updated: 26 December 2023 at 1:11pm EST

Dr. Shane A. Johnson Ph.D. Net Worth




The estimated Net Worth of Shane Aaron Johnson is at least $88.3 mil dollars as of 6 January 2022. Dr Johnson owns over 8,500 units of InMed Pharmaceuticals stock worth over $88,333 and over the last 3 years he sold INM stock worth over $0.

Dr D INM stock SEC Form 4 insiders trading

Dr has made over 3 trades of the InMed Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 8,500 units of INM stock worth $10,710 on 6 January 2022.

The largest trade he's ever made was buying 8,500 units of InMed Pharmaceuticals stock on 6 January 2022 worth over $10,710. On average, Dr trades about 3,599 units every 9 days since 2021. As of 6 January 2022 he still owns at least 304,595 units of InMed Pharmaceuticals stock.

You can see the complete history of Dr Johnson stock trades at the bottom of the page.





Dr. Shane A. Johnson Ph.D. biography

Dr. Shane A. Johnson Ph.D. is the Sr. VP & GM of BayMedica at InMed Pharmaceuticals.



What's Dr D's mailing address?

Shane's mailing address filed with the SEC is C/O INMED PHARMACEUTICALS INC., 310-815 WEST HASTINGS ST., VANCOUVER, A1, V6C1B4.

Insiders trading at InMed Pharmaceuticals

Over the last 4 years, insiders at InMed Pharmaceuticals have traded over $43 worth of InMed Pharmaceuticals stock and bought 153,613 units worth $127,277 . The most active insiders traders include William J Garner, Eric A Adams y Andrew Hull. On average, InMed Pharmaceuticals executives and independent directors trade stock every 86 days with the average trade being worth of $3,718. The most recent stock trade was executed by Alexandra Diane Janet Mancini on 31 July 2024, trading 240 units of INM stock currently worth $43.



What does InMed Pharmaceuticals do?

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.



What does InMed Pharmaceuticals's logo look like?

InMed Pharmaceuticals Inc. logo

Complete history of Dr Johnson stock trades at InMed Pharmaceuticals

Fecha
#
Empresa
Persona
Trans.
Transacción
Acciones Precio por acción Precio total Acciones después de Fuente
6 Jan 2022 Shane Aaron Johnson
Sr VP y General Manager
Comprar 8,500 $1.26 $10,710
6 Jan 2022
304,595
30 Dec 2021 Shane Aaron Johnson
Sr VP y General Manager
Comprar 8,093 $1.33 $10,764
30 Dec 2021
296,095
15 Nov 2021 Shane Aaron Johnson
Sr VP y General Manager
Comprar 5,000 $1.37 $6,850
15 Nov 2021
288,002


InMed Pharmaceuticals executives and stock owners

InMed Pharmaceuticals executives and other stock owners filed with the SEC include: